Nita Williams

628 total citations
23 papers, 461 citations indexed

About

Nita Williams is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Nita Williams has authored 23 papers receiving a total of 461 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Hematology, 10 papers in Molecular Biology and 6 papers in Genetics. Recurrent topics in Nita Williams's work include Multiple Myeloma Research and Treatments (8 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Chronic Myeloid Leukemia Treatments (3 papers). Nita Williams is often cited by papers focused on Multiple Myeloma Research and Treatments (8 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Chronic Myeloid Leukemia Treatments (3 papers). Nita Williams collaborates with scholars based in United States, United Kingdom and Spain. Nita Williams's co-authors include Charis Eng, Scott D. Jewell, Gregory T. MacLennan, Daniel D. Sedmak, Mythily Srinivasan, Virginia A. LiVolsi, Don M. Benson, Yvonne A. Efebera, Manuel López-Alonso and Salud Borrego and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Nita Williams

22 papers receiving 449 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nita Williams United States 9 274 146 97 87 76 23 461
Jessica Heinrichs United States 15 169 0.6× 111 0.8× 66 0.7× 280 3.2× 91 1.2× 23 756
O. I. Olopade United States 9 209 0.8× 195 1.3× 136 1.4× 44 0.5× 22 0.3× 14 491
Su‐Chen Lee Taiwan 13 212 0.8× 97 0.7× 80 0.8× 21 0.2× 26 0.3× 20 378
Dmitry S. Mikhaylenko Russia 10 167 0.6× 80 0.5× 86 0.9× 33 0.4× 37 0.5× 43 369
W D Figg United States 5 147 0.5× 99 0.7× 96 1.0× 82 0.9× 17 0.2× 6 357
Daniel Torres‐Moreno Spain 12 114 0.4× 112 0.8× 58 0.6× 31 0.4× 41 0.5× 24 399
Dres Damgaard Denmark 15 191 0.7× 79 0.5× 91 0.9× 36 0.4× 26 0.3× 25 586
Qingyi Wei United States 11 383 1.4× 132 0.9× 149 1.5× 30 0.3× 91 1.2× 29 548
Yoshitsugu Miki Japan 6 156 0.6× 234 1.6× 77 0.8× 20 0.2× 51 0.7× 8 487

Countries citing papers authored by Nita Williams

Since Specialization
Citations

This map shows the geographic impact of Nita Williams's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nita Williams with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nita Williams more than expected).

Fields of papers citing papers by Nita Williams

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nita Williams. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nita Williams. The network helps show where Nita Williams may publish in the future.

Co-authorship network of co-authors of Nita Williams

This figure shows the co-authorship network connecting the top 25 collaborators of Nita Williams. A scholar is included among the top collaborators of Nita Williams based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nita Williams. Nita Williams is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cottini, Francesca, Ying Huang, Nita Williams, et al.. (2021). Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients. Frontiers in Oncology. 10. 575168–575168. 11 indexed citations
2.
Zhao, Qiuhong, Don M. Benson, Patrick Elder, et al.. (2020). AL Amyloidosis: The Prognostic Impact of Maintenance Therapy Following ASCT. Biology of Blood and Marrow Transplantation. 26(3). S229–S230. 1 indexed citations
3.
Cottini, Francesca, Nita Williams, Naresh Bumma, et al.. (2020). Daratumumab-induced lymphopenia predicts adverse events and outcomes in patients with myeloma.. Journal of Clinical Oncology. 38(15_suppl). e20534–e20534. 1 indexed citations
4.
Zhao, Qiuhong, Nita Williams, Nidhi Sharma, et al.. (2020). Comparison of Patient Outcomes with Two Different Formulations of Melphalan As Conditioning Chemotherapy for Autologous Stem Cell Transplantation in Multiple Myeloma. Blood. 136(Supplement 1). 1–1. 2 indexed citations
5.
Sharma, Nidhi, David Chen, Qiuhong Zhao, et al.. (2019). Lenalidomide and Vorinostat Maintenance after Autologous Transplantation in Multiple Myeloma: Long- Term Follow-Up. Biology of Blood and Marrow Transplantation. 26(1). 44–49. 4 indexed citations
6.
Hamilton, Nicholas, et al.. (2019). Effect of Age on Healthcare Utilization in Patients with Sickle Cell. Blood. 134(Supplement_1). 1019–1019.
7.
Huang, Ying, Nita Williams, Nidhi Sharma, et al.. (2018). Ninety-minute daratumumab infusion is safe in multiple myeloma. Leukemia. 32(11). 2495–2518. 51 indexed citations
8.
Williams, Nita, et al.. (2018). Home Based Primary Care for Patients with Sickle Cell Disease. Blood. 132(Supplement 1). 4721–4721. 1 indexed citations
9.
Sharma, Nidhi, Nita Williams, Don M. Benson, et al.. (2017). Shingles Occurs in Only 0.5% of Myeloma Patients on Any Dose of Antiviral Prophylaxis. Blood. 130. 4645–4645. 1 indexed citations
10.
Williams, Nita, Nidhi Sharma, Don M. Benson, et al.. (2017). B-Cell Lymphoma Patients Have a 10% Risk of Shingles, 7% in Cutaneous T-Cell Lymphoma. Blood. 130. 3356–3356. 1 indexed citations
11.
Huang, Ying, Nita Williams, Nidhi Sharma, et al.. (2017). Ninety-Minute Daratumumab Infusion Is Safe in Multiple Myeloma. Blood. 130. 1889–1889. 2 indexed citations
12.
Williams, Nita, Nidhi Sharma, Yvonne A. Efebera, et al.. (2016). Anti-Depressant Use in Patients with Multiple Myeloma Less Common Than Expected. Blood. 128(22). 2420–2420. 3 indexed citations
13.
Sborov, Douglas W., Don M. Benson, Nita Williams, et al.. (2015). Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma. British Journal of Haematology. 171(1). 74–83. 20 indexed citations
14.
Hofmeister, Craig C., Nita Williams, Susan M. Geyer, et al.. (2014). A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma. Leukemia & lymphoma. 56(4). 1043–1049. 8 indexed citations
15.
Lee, Xuhui, Nita Williams, Ping Wen, et al.. (2007). Pilot Study of Rosiglitazone Therapy in Women with Breast Cancer: Effects of Short-term Therapy on Tumor Tissue and Serum Markers. Clinical Cancer Research. 13(1). 246–252. 78 indexed citations
16.
Bekaii‐Saab, Tanios, et al.. (2006). A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma. BMC Cancer. 6(1). 278–278. 40 indexed citations
17.
Morrison, Carl, et al.. (2004). Molecular Classification of Parathyroid Neoplasia by Gene Expression Profiling. American Journal Of Pathology. 165(2). 565–576. 25 indexed citations
18.
Borrego, Salud, Fred A. Wright, Raquel M. Fernández, et al.. (2003). A Founding Locus within the RET Proto-Oncogene May Account for a Large Proportion of Apparently Sporadic Hirschsprung Disease and a Subset of Cases of Sporadic Medullary Thyroid Carcinoma. The American Journal of Human Genetics. 72(1). 88–100. 81 indexed citations
19.
Jewell, Scott D., Mythily Srinivasan, Nita Williams, et al.. (2002). Analysis of the Molecular Quality of Human Tissues. American Journal of Clinical Pathology. 118(5). 733–741. 112 indexed citations
20.
Ashe, William F. & Nita Williams. (1965). Occupational Raynaud??s II. Journal of Occupational and Environmental Medicine. 7(4). 174–174. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jessica Heinrichs Breakdown of academic impact, for papers by O. I. Olopade Breakdown of academic impact, for papers by Su‐Chen Lee Breakdown of academic impact, for papers by Dmitry S. Mikhaylenko Breakdown of academic impact, for papers by W D Figg Breakdown of academic impact, for papers by Daniel Torres‐Moreno Breakdown of academic impact, for papers by Dres Damgaard Breakdown of academic impact, for papers by Qingyi Wei Breakdown of academic impact, for papers by Yoshitsugu Miki
Rankless by CCL
2026